SCHEMBL4964952

SCHEMBL4964952

COC(=O)N1CCN(c2ccc(C3(C(=O)N[C@H]4CC[C@H](O)CC4)CC3)c(F)c2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 4/20 0.45
MAPT P10636 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.41
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 2/20 0.41
BMPR1B O00238 2/20 0.40
BMPR1A P36894 2/20 0.40
TGFBR1 P36897 2/20 0.40
ACVRL1 P37023 2/20 0.40
ACVR1 Q04771 2/20 0.40
ALK Q9UM73 4/20 0.39
GFER P55789 1/20 0.38
CYP3A4 P08684 2/20 0.37
HSD17B10 Q99714 2/20 0.37
USP2 O75604 1/20 0.37
MAPK1 P28482 3/20 0.37
MEN1 O00255 2/20 0.37
CYP2C19 P33261 1/20 0.37
SYK P43405 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4964877 1.00 PDK2 (0.45) PDK2MAPTSMN1; SMN2L3MBTL1KMT2A
SCHEMBL4963551 0.92 PDK2 (0.46) PDK2MAPTSMN1; SMN2L3MBTL1KMT2A
SCHEMBL4963030 0.92 PDK2 (0.46) PDK2MAPTSMN1; SMN2L3MBTL1KMT2A
SCHEMBL4964668 0.91 MAPT (0.47) PDK2MAPTSMN1; SMN2L3MBTL1KMT2A
SCHEMBL4962318 0.91 MAPT (0.47) PDK2MAPTSMN1; SMN2L3MBTL1KMT2A
SCHEMBL4963132 0.84 L3MBTL1 (0.49) PDK2MAPTSMN1; SMN2L3MBTL1KMT2A
SCHEMBL4963137 0.84 L3MBTL1 (0.49) PDK2MAPTSMN1; SMN2L3MBTL1KMT2A
SCHEMBL4011307 0.83 PDK2 (0.44) PDK2MAPTSMN1; SMN2L3MBTL1KMT2A
SCHEMBL5950347 0.83 PDK2 (0.44) PDK2MAPTSMN1; SMN2L3MBTL1KMT2A
SCHEMBL6414235 0.83 PDK2 (0.46) PDK2MAPTSMN1; SMN2L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US claimed
EP-1773780-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP disclosed
EP-1773780-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-04-18 EP disclosed
WO-2006012227-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO disclosed
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288338-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 PDK2 1025/4885MAPT 3691/4885SMN1; SMN2 3497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.